PPBTNasdaqPharmaceutical PreparationsFiscal year ends December 31
PURPLE BIOTECH LTD.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026
$1.08−0.06 (-5.26%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 40.0
- Dividend yield
- –
PURPLE BIOTECH LTD. revenue by segment
By business segment
| Revenue | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Pain and Hypertension [Member] | $1.00M | $1.00M | $1.00M | $100.00K | 100.0% | 0.0% |
| Total Reportable Segments [Member] | $1.00M | $1.00M | $1.00M | $100.00K | 100.0% | 0.0% |
| Oncology [Member] | – | – | $0 | $0 | – | – |
| Reconciliations [Member] | – | – | $0 | $0 | – | – |
| Operating income | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|
| Pain and Hypertension [Member] | – | -$3.07M | -$4.73M | -$6.67M | – |
| Total Reportable Segments [Member] | – | -$5.88M | -$7.95M | -$8.63M | – |
| Oncology [Member] | – | -$2.82M | -$3.22M | -$1.95M | – |
| Reconciliations [Member] | – | -$1.27M | -$121.00K | -$3.34M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Purple Biotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.